| sess_sda-2026-04-01- | SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re | 0.83 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-014 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.81 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-20260401231108 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.53 | 1 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-9137255b |
| sess_sda-2026-04-01- | Can gut-brain axis modulation prevent or slow Alzheimer's disease pathology? | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-003 |
| sess_sda-2026-04-01- | How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease | 0.90 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-002 |
| sess_sda-2026-04-01- | What are the most promising therapeutic strategies for targeting TREM2 in Alzhei | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-001 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.87 | 3 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| sess_sda-2026-04-01- | Sleep disruption as cause and consequence of neurodegeneration | 0.91 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-18cf98ca |
| sess_sda-2026-04-01- | RNA binding protein dysregulation across ALS FTD and AD | 0.88 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-68d9c9c1 |
| sess_sda-2026-04-01- | Synaptic pruning by microglia in early AD | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-691b42f1 |
| sess_sda-2026-04-01- | Mitochondrial transfer between astrocytes and neurons | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-89432b95 |
| sess_sda-2026-04-01- | Epigenetic clocks and biological aging in neurodegeneration | 0.93 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-bc5f270e |
| sess_sda-2026-04-01- | Perivascular spaces and glymphatic clearance failure in AD | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-ee5a5023 |
| sess_sda-2026-04-01- | What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-20260401-225149 |
| sess_SDA-2026-04-06- | TREM2 Therapeutic Strategy Post-INVOKE-2 | 0.93 | 7 | 4 | completed | 2026-04-06 | SDA-2026-04-06-gap-001 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early AD | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early Alzheimer's Disease | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 |
| sess_SDA-2026-04-04- | Tau propagation mechanisms and therapeutic interception points | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| sess_SDA-2026-04-04- | Senescent cell clearance as neurodegeneration therapy | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| sess_analysis_sea_ad | What are the cell-type specific vulnerability mechanisms in Alzheimer's disease | 0.68 | 0 | 4 | completed | 2026-04-04 | analysis_sea_ad_001 |
| sess_SDA-2026-04-04- | SEA-AD Single-Cell Analysis: Cell-Type Vulnerability in Alzheimer's Disease | 0.88 | 5 | 4 | completed | 2026-04-04 | SDA-2026-04-04-analysis_sea_ad_001 |
| sess_SDA-2026-04-04- | Which metabolic biomarkers can distinguish therapeutic response from disease pro | 0.92 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| sess_SDA-2026-04-04- | How do neurodegeneration gene expression patterns in SEA-AD differ from other po | 0.94 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222549-20260402 |
| sess_SDA-2026-04-04- | How do astrocyte-neuron metabolic interactions change during disease progression | 0.93 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| sess_SDA-2026-04-03- | The debate mentioned gene expression profiling but did not specify which neural | 0.93 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| sess_SDA-2026-04-03- | While ketone metabolism was discussed as therapeutic, the debate revealed no cle | 0.80 | 8 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| sess_SDA-2026-04-03- | The debate highlighted TFEB's role in mitochondrial-lysosomal coupling but could | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 6 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v2-20260402 |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 6 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-20260402 |
| sess_SDA-2026-04-03- | Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| sess_SDA-2026-04-03- | Comprehensive analysis of immune cell subtypes in neurodegeneration: microglia s | 0.85 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| sess_SDA-2026-04-03- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.92 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-seaad-20260402025452 |
| sess_SDA-2026-04-03- | Analyze circuit-level changes in neurodegeneration using Allen Institute Neural | 0.95 | 6 | 4 | completed | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| sess_SDA-2026-04-03- | Investigate prion-like spreading of tau pathology through connected brain region | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-tau-prop-20260402003221 |
| sess_SDA-2026-04-03- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.90 | 7 | 4 | completed | 2026-04-03 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| sess_SDA-2026-04-03- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.95 | 7 | 4 | completed | 2026-04-03 | SDA-2026-04-03-gap-seaad-v3-20260402063622 |
| sess_SDA-2026-04-03- | What cell types are most vulnerable in Alzheimer's Disease based on SEA-AD trans | 0.95 | 6 | 4 | completed | 2026-04-03 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| sess_SDA-2026-04-02- | What cell types are most vulnerable in Alzheimer's Disease based on SEA-AD trans | 0.95 | 7 | 4 | completed | 2026-04-03 | SDA-2026-04-02-gap-seaad-v2-20260402032945 |
| debate-seaad-2026040 | Cell-type specific expression patterns of neurodegeneration genes in SEA-AD | 0.68 | 5 | 3 | completed | 2026-04-02 | analysis-SEAAD-20260402 |
| sess_SDA-2026-04-02- | How does metabolic reprogramming (glucose metabolism shifts, brain insulin resis | 0.73 | 3 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-v2-5d0e3052 |
| sess_SDA-2026-04-02- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.71 | 4 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402 |
| sess_SDA-2026-04-02- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.74 | 3 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-seaad-v4-20260402065846 |
| sess_SDA-2026-04-02- | Epigenetic reprogramming in aging neurons | 0.95 | 7 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-epigenetic-reprog-b685190e |
| sess_SDA-2026-04-02- | Extracellular vesicle biomarkers for early AD detection | 0.87 | 7 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-ev-ad-biomarkers |
| sess_SDA-2026-04-02- | Investigate prion-like spreading of tau pathology through connected brain region | 0.88 | 6 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| sess_SDA-2026-04-02- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.57 | 0 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-seaad-v3-20260402063622 |
| sess_SDA-2026-04-02- | Senescent cell clearance as neurodegeneration therapy | 0.95 | 7 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| sess_SDA-2026-04-02- | Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for | 0.90 | 7 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 |
| sess_SDA-2026-04-02- | The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, bu | 0.89 | 7 | 4 | completed | 2026-04-02 | SDA-2026-04-02-gap-001 |